A Clinicopathological Study of Primary Small Intestinal Cancer with Emphasis on Cellular Characteristics by NOGAKI Koji et al.
Showa Univ J Med Sci 24（4）, 309～318, December 2012
A Clinicopathological Study of Primary Small Intestinal Cancer  
with Emphasis on Cellular Characteristics
Koji NOGAKI1，2）, Nobuyuki OHIKE1）, Manabu TAKAHASHI3）,  
Genki TSUKUDA1）, Yusuke WADA1，2）, Kodai HIRABAYASHI1）,  
Yojiro KAWAMURA1）, Toshiaki KUNIMURA4）, Kazuhide KUMAGAI5）,  
Masahiko MURAKAMI2） and Toshio MOROHOSHI1）
Abstract : We examined the clinicopathological profiles and cellular charac-
teristics of 10 cases of surgically resected primary small intestinal cancers 
（excluding duodenal cancers）.  Histological examination revealed nine adeno-
carcinomas and one sarcomatoid carcinoma.  Invasion depth was subserosal 
in five cases, serosal in four cases and to the adjacent transverse colon in 
the remaining case.  Metastasis was present in lymph node in seven cases, 
in distant organs in six, and in the peritoneum in seven cases.  Of the 10 
cases, 7 underwent postoperative chemotherapy, and 6 of the eight traceable 
patients died from the disease （mean period of survival : 386 days）.  Histo-
morphologically, eight of nine adenocarcinomas showed an intestinal phenotype 
（unclassiable in the other） in the upper layer, while in the lower layer, there 
showed an intestinal phenotype and ve a non-intestinal phenotyp.  Immuno-
histochemistry revealed a mean positive rate in the upper / lower layers as 
follows : 93％ / 86％ and 38％ / 29％ by intestinal markers CDX2 and MUC2 ; 
19％ / 28％ and 13％ / 32％ by pancreatobiliary markers CK7 and MUC1 ; and 
4％ / 19％ and 2％ / 9％ by gastric markers MUC5AC and MUC6, respectively.  
Thus, the intestinal phenotype predominated in almost all small intestinal 
cancer in this study, although some showed a transformation to non-intestinal 
or hybrid phenotypes with tumor progression.  Flexible management for the 
diversity and transformation of cellular characteristics is therefore recommended 
treating and diagnosing small intestinal cancers.
Key words : small intestinal cancer, clinicopathological study, cellular characteris-
tics, intestinal phenotype
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Introduction
　Cancer of the small intestine is often not detected until it reaches an advanced stage due 
to the late presentation of symptoms and the difficulty in performing endoscopic examina-
tions.  Many cases are also unsuitable for radical resection or have postoperative cancer 
recurrence, making chemotherapy frequently appropriate as an adjuvant or multidisciplinary 
therapy.  However, there are no established chemotherapy regimens specic to small intesti-
nal cancer as this cancer is extremely rare, comprising ＜2％ of all cases of gastrointestinal 
malignancies1, 2） and successful results have not yet been obtained3）.
　The need for “personalized medicine” is being increasingly considered.  This involves 
medication selection and regimen determination based on the sensitivity of an individual’s 
cancer cells to anti-cancer drugs or cancer cell-specific characteristics such as the presence 
of tumor-associated antigens.  Although small intestinal cancer is generally considered to 
resemble colon cancer histomorphologically, the keratin proles and genetic abnormalities of 
this disease differ from those of colon cancer4-8）.  The study focused on the cellular charac-
teristics of small intestinal cancer, since few such studies have been done.
　The aim of this study was to clarify the cellular characteristics of small intestinal cancer 
by histomorphological and immunohistochemical analyses.  We expect that the results will be 
useful when considering the histogenesis of small intestinal cancer as well as for its diagno-
sis and treatment.
Materials and Methods
Case selection
　We reviewed 65 cases of malignant small bowel neoplasms （excluding duodenal tumors）, 
which were surgically resected during the 7 years from September 2003 to September 
2010 at the authors’ facilities.  Among these, 26 cases （40％） were reported as metastatic 
carcinomas to the small intestine, 23 as peritoneal dissemination of abdominal malignancy, 
and 3 as metastasis from lung cancer.  The remaining 39 primary tumor cases included 
10 cases of carcinoma （15％） （9 adenocarcinoma and 1 sarcomatoid carcinoma）, 12 cases 
（18％） of malignant lymphoma, 8 cases （12％） of gastrointestinal stromal tumor （GIST）, 3 
cases （5％） of leiomyosarcoma, 1 case （2％） of neuroendocrine tumor （carcinoid）, and 5 
unclassied cases （8％） as follows ; one case in which the tumor was mainly located in the 
terminal ileum, but also involved the cecum ; one in which a tumor equally involved the 
jejunum and pancreas ; two in which a primary ileal carcinoma was suspected, but another 
carcinoma was observed concurrently in another organ （colon）; and one in which it was 
difcult to distinguish whether the tumor was a recurrence of gastric cancer after more than 
5 postoperative recurrence-free years or a primary jejunal carcinoma.  The subject of the 
present study were the 10 carcinoma cases
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Clinicopathological study
　14 clinicopathological factors―age, sex, chief complaint, localization, size, tumor marker, 
macroscopic type, histological type, invasion depth, presence of lymph node metastases, pres-
ence of distant metastases and / or peritoneal dissemination, chemotherapeutic regimen, and 
prognosis were studied.
Analysis of cellular characteristics
　We conducted histological and immunohistochemical analyses for determining the cellular 
characteristics of adenocarcinoma cases.
Histological analysis
　We classified the neoplastic glands histomorphologically into intestinal and non-intestinal 
phenotypes.  The intestinal phenotype was characterized by similarities with colorectal 
adenomas or cancers showing tall columnar epithelium with pseudostratified, spindle nuclei 
and chromophilic （basophilic or acidophilic） cytoplasm.  Goblet and paneth cells were 
also considered as related findings.  On the other hand, the neoplastic glands lacking these 
characteristics were classied into the non-intestinal phenotype.  For each case, 1 or 2 slides 
including all layers of the tumor were selected and observed by dividing the lesions into 
upper and lower layers.  The upper layer was considered as a relatively early stage lesion of 
the tumor and the lower layer as the invasive front.  In cases involving a mixture of intes-
tinal and non-intestinal phenotype, the dominant appearance was agreed upon by multiple 
observers （K.N, N.O, T.M）.
Immunohistochemical analysis
　Immunohistochemical staining was performed using an avidin-biotin complex detection 
system （BenchMark XT / LT automated slide stainer ; Ventana Medical Systems, Inc., Tucson, 
AZ, USA）.  We prepared 3-μm sections for immunostaining from formalin-fixed, paraffin-
embedded blocks used in the histological analysis.  Markers included MUC1 （Ma695, Leica 
Biosystems Newcastle Ltd, Newcastle, UK ; diluted ×100）, MUC2 （Ccp58, Leica Biosystems ; 
diluted ×200）, MUC5AC （CLH2, Leica Biosystems ; diluted ×200）, MUC6 （CLH5, Leica 
Biosystems ; diluted ×50）, CK7 （OV-TL12 / 30, DAKO North America, Inc.  CA, USA ; 
diluted done）, CDX2 （EPR2764Y, Nichirei Bioscience Inc, Tokyo, Japan ; diluted done）, 
CA19-9 （C241 : 5 : 1 : 4, Leica Biosystems ; diluted ×200）, and CEA （COL-1, Nichirei Bio-
science Inc, Tokyo japan ; diluted done）.  Positive staining at the apical membrane of tumor 
cells was considered signicant for MUC1, nuclear-positive staining for CDX2, and cytoplas-
mic staining for the remaining markers.  MUC2 and CDX2 were recognized as intestinal 
phenotypic markers, MUC1 and CK7 as pancreatobiliary phenotypic markers, and MUC5AC 
and MUC6 as gastric phenotypic markers.  All markers were evaluated by the proportion 
of positive cells in numerical values separately for the upper and lower layers of the lesions, 
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which almost represented the proportions in the whole tumor.
Results
Clinicopathological characteristics （Table 1）
　The patients included 6 males and 4 females with a mean age of 62 years （age range : 
Table 1　Clinicopathological characteristics
　 Case 1 Case 2 Case 3 Case 4 Case 5
Age （ys.） 34 66 37 63 65
Sex male female male female male
Chief complaint ileus ileus ileus abd tumor ileus
Localization ileum ileum jejunum ileum jejunum
Macroscopic type ulcerated ulcerated ulcerated ulcerated ulcerated
Microscopic type tub＞muc tub tub muc＞ tub tub＞ por
Dominant phenotype
　upper layer intestinal intestinal intestinal intestinal intestinal
　lower layer non-intestinal non-intestinal non-intestinal intestinal non-intestinal
Invasion depth ss se ss ss ss
Lymph node metastasis ＋ ＋ - ＋ ＋
Distant metastasis - ＋ ＋ ＋ -
Peritoneal dissemination - ＋ ＋ - ＋
Chemotherapy TS-1 TS-1 TS-1→UFT TS-1 none
Outcome
（days after surgery） 1460 alive 500 alive 416 dead 88 dead 551 dead
　 Case 6 Case 7 Case 8 Case 9 Case 10
Age （ys.） 66 76 70 87 51
Sex female female male male male
Chief complaint ileus ileus abd pain anemia abd tumor
Localization ileum jejunum jejunum jejunum ileum
Macroscopic type ulcerated ulcerated ulcerated ulcerated protuberant
Microscopic type tub tub por＞muc tub＞muc sar ca
Dominant phenotype
　upper layer intestinal intestinal unclassiable intestinal -
　lower layer intestinal non-intestinal unclassiable intestinal -
Invasion depth se si se ss se
Lymph node metastasis ＋ - ＋ ＋ unknown
Distant metastasis ＋ - ＋ ＋ unknown
Peritoneal dissemination ＋ ＋ ＋ ＋ unknown
Chemotherapy TS-1 TS-1＋CPT11 FOLFOX none none
Outcome
（days after surgery） 550 dead 665 dead 50 dead unknown unknown
Abbreviations : tub ; tubular adenocarcinoma, muc ; mucinous （colloid） carcinoma, sar ca ; sarcomatoid 
carcinoma
ss ; subserosal invasion, se ; serosal invasion, si ; direct invasion to adjacent organs, ＋ ; present, - ; absent
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34-87 years）.  Intestinal obstruction （also called ileus） symptoms were the most frequent 
chief complaint.  None of the case was complicated by specific inflammatory or hereditary 
diseases such as Crohn’s disease or  Peutz–Jeghers syndrome.  High serum CA19-9 and CEA 
levels were found in 2 cases each （along with the growth of postoperative residual tumors, 
high serum CA19-9 and CEA levels were observed in 6 cases and 3 cases, respectively）. 
Surgical methods were partial resection of the small intestine along with feeding arteries 
aimed at lymphadenectomy in all cases.  All tumors were macroscopically advanced cancers 
showing protuberant type in 1 case （Case 10） and ulcerated type in the remaining 9 cases, 
with the latter frequently showing annular constriction.  The mean tumor diameter was 
7.3 cm （range : 3.0-21.0 cm）.  All tumors were solitary and there were no hamartomatous 
or adenomatous polyps in the surrounding mucosa.  Histologically, the protuberant type 
（case 10） was sarcomatoid carcinoma, while the nine ulcerated types were tubular adeno-
carcinomas, including mucinous （colloid） carcinoma component in 4 cases.  In addition, 
2 cases （cases 2 and 9） showed an adenomatous component in the periphery, but those 
were indistinguishable from well-differentiated, low-grade adenocarcinoma.  Invasion depth 
was subserosal in 5 cases and serosal in 4 cases, while invasion into the adjacent transverse 
colon was observed in one case （case 7）.  In addition, lymph node metastasis, distant organ 
metastasis, and peritoneal metastasis were observed in 7 cases, 6 cases, and 7 cases, respec-
tively.  Postoperative chemotherapy was administered to 7 patients of which 6 were treated 
by TS1 alone or by a combination of TS1 and other agents, and 1 by FOLFOX.  Postop-
erative prognoses were traceable in 8 cases.  Tumor-related death occurred in 6 patients and 
they were identified with a mean survival period of 386 days （range : 50-665 days）.  In 
the remaining 2 cases, one patient （case 2） is alive 500 days after the surgery with recur-
rence and another patient （case 1） is alive 1460 days after surgery without any recurrence 
（treated with adjuvant chemotherapy）.
Cellular characteristics
　All nine adenocarcinoma cases showed heterogeneous （composite or combined） cellular 
characteristics histomorphologically （Figure 1）; however, when classifying the dominant 
features into intestinal and non-intestinal phenotypes for each layer, 8 cases were classified 
as intestinal and 1 case as unclassifiable in the upper layer, whereas 3 cases were classified 
as intestinal, 5 cases as non-intestinal, and 1 as unclassifiable in the lower layer （Table 1）. 
The neoplastic glands of the non-intestinal phenotype were mainly composed of monolayer 
cuboidal epithelial cells with round nuclei and eosinophilic or clear cytoplasm showing 
characteristics of pancreaticobiliary or gastric phenotypes （Figure 1）.  A case of poorly 
differentiated adenocarcinoma showing medullary proliferation in most of the tumor was 
unclassiable （case 8）.  In the immunohistochemical study, the proportional range of positive 
cells was wide for all markers in both layers, with the mean proportions in the upper / lower 
layers as follows （Table 2）: 93％ / 86％ and 38％ / 29％ for the intestinal phenotypic markers 
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CDX2 and MUC2, respectively ; 13％ / 32％ and 19％ / 28％ for the pancreatobiliary phe-
notypic markers MUC1 and CK7, respectively ; and 4％ / 19％ and 2％ / 9％ for the gastric 
phenotypic markers MUC5AC and MUC6, respectively.  The summarized data indicated that 
the expression of intestinal phenotypic markers were predominant in both layers, but that a 
mild increase in the  expression of non-intestinal phenotypic markers was observed in the 
lower layer ; this seemed to correspond to the histomorphological results （Figure 1）.  Lymph 
node metastatic lesions showed similar histomorphological and immunohistochemical ndings 
to those of the lower layer （data not shown）.
Discussion
　The efficacy of chemotherapy administered for small intestinal cancer remains unknown 
because this cancer is extremely rare and many such cancers are detected once in a locally 
Fig. 1.   Histological and immunohistochemical ndings of small intestinal adenocarcinoma （case 1）
Tumor shows a heterogeneous feature, although the intestinal （INT）-phenotype is dominant in the 
upper layer while the pancreatobiliary （PB） phenotype is dominant in the lower layer. Note the 
CDX2 nuclear staining in the former and MUC1 at staining at the apical membrane in the latter.
Table 2　Immunohistochemical study
Intestinal maker Pancreatibiliary marker Gastric marker Others
MUC2 CDX2 MUC1 CK7 MUC5AC MUC6 CA19-9 CEA
Upper layer
38％ 93％ 13％ 19％ 4％ 2％ 77％ 84％
（3-90） （70-100） （0-40） （0-100） （0-30） （0-8） （50-100） （70-95）
Lower layer
29％ 86％ 32％ 28％ 19％ 9％ 94％ 93％
（3-90） （40-100） （1-80） （0-100） （0-80） （0-70） （80-100） （90-95）
（upper stand ; mean propotion of positive cells, lower stan ; range）
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advanced or distantly metastasized status1, 2, 9, 10）, as also observed in this study.  Personalized 
medicine involves medication selection and regimen determination based on the cancer cell-
specific chemotherapeutic sensitivity or characteristic phenotypes （e.g., presence of tumor-
associated antigens） to improve chemotherapy efficacy.  We believe that our study on the 
cellular characteristics of small intestinal cancer will be benecial for developing future such 
chemotherapeutic strategies against small intestinal cancer.
　Most case of small intestinal cancer （adenocarcinoma） studied herein were histomor-
phologically heterogeneous.  Hence, we were forced to evaluate the cellular characteristics 
based on dominant features along with the agreement of multiple observers, although several 
suggestive results were obtained.  This study showed that intestinal phenotypic features were 
overwhelmingly predominant in the upper layer, which implies that small intestinal adeno-
carcinoma predominantly occurs with an intestinal phenotype.  This is consistent with the 
description that histological features of small intestinal cancers are characterized by intestinal 
phenotypic adenocarcinoma similar to colon cancer11）.  On the other hand, features lacking 
intestinal phenotypic characteristics were dominant in the lower layer （invasive front）, which 
suggested that small intestinal adenocarcinomas, originally developing with predominantly 
intestinal phenotypic characteristics, may lose those characteristics and add or change differ-
ent phenotypes with invasive progression.  Such phenomena are not surprising in carcinomas 
arising in transitional mucosa or mucosa showing frequent metaplastic changes12, 13）, and 
thus are seemingly inevitable also for small intestinal cancer.  Immunohistochemically, the 
intestinal phenotype was predominant throughout the tumors because the positive rate of 
intestinal phenotypic marker CDX2 was overwhelmingly high in both layers compared to 
that of other markers, and the positive rates of pancreatobiliary phenotypic markers （MUC1 
and CK7） and gastric phenotypic markers （MUC5AC and MUC6） only increased mildly in 
line with the histological features.  Thus, these results suggest that selection of anti-cancer 
drugs centering on medications that are efcacious for intestinal phenotypic adenocarcinoma 
as well as combining medications that correspond to the transformation of cellular character-
istics may increase their combined effects.
　There are several histopathological differences between small intestinal cancer and colorec-
tal cancer4-8）.  Poorly differentiated carcinoma and sarcomatoid carcinoma are sometimes 
observed in small intestinal cancers （case 8 and case 10 in this study）9, 14-17）, but such types 
are extremely rare in colorectal cancer.  Small intestinal adenocarcinomas show expression of 
pancreatobiliary markers ［e.g. keratin 7, MUC1, and CA19-9 （see Table 2）］ at a higher rate 
compared to colorectal adenocarcinomas.  Chen and Wang.4） reported that all small intestinal 
adenocarcinomas showed a variable degree of CK7 expression （diffuse in 54％ and focal in 
46％）; in contrast, only 4％ in this study showed focal expression in secondary colorectal 
adenocarcinomas.  We also confirmed that only 7 （4％） of 169 colorectal adenocarcinomas 
exhibited a MUC1 positive cell ratio of ＞50％, while ratios this high were shown in 41 
（70％） of 59 pancreatic adenocarcinomas and 3 （30％） of 10 small intestinal adenocarcino-
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mas18）.   Moreover, genetic abnormalities of colorectal cancer （e.g., APC gene mutations） do 
not always apply to small intestinal cancers 5, 6, 19）.  With regard to the histogenesis, it remains 
controversial whether an adenomacarcinoma progression sequence, which is well described 
in colorectal cancer, is the major pathway in small intestinal cancer because few study have 
been done involving early stage lesions.  Although adenomatous component were observed 
in the tumor periphery in two of the present cases, the phenotype was still difficult to 
discriminate from well-differentiated, low grade adenocarcinoma （Chang et al described this 
as “peritumoral dysplasia”9））.  Thus, the adenomacarcinoma sequence was not proven in any 
case.  In genetic susceptibility, no present cases involved hamartomatous or adenomatous 
polyps, suggestive of Peutz-Jeghers syndrome or familial adenomatous polyposis.  Lynch syn-
drome was also not noted in any case, although the level of microsatellite instability （MSI） 
should be analyzed in future studies because high MSI rates of 10-25％ have been already 
described in small intestinal cancers11, 20-23）.
　In conclusion, this study of the clinicopathological features of small intestinal cancers 
suggested the need of chemotherapy as an adjunctive or multidisciplinary therapy.  Most 
small intestinal cancers （adenocarcinomas） develop predominantly with intestinal phenotypic 
characteristics as a major characteristic, but they show intrinsically heterogeneous profiles. 
This could indicate the loss of intestinal phenotypic characteristics with tumor progression 
or an association with non-intestinal phenotypic characteristic.  Higher case-number studies 
are now needed to better analyze the transformative effects on clinicopathological factors 
and prognoses.  Indeed, exible management for the diversity and transformation of cellular 
characteristics may be desirable when treating and diagnosing small intestinal cancers.
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